NCT04414657

Brief Summary

Mono-centric. Blood sampling for biobank development, including linkage to patient data (resource for research on COVID19).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2020

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 9, 2020

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 2, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 4, 2020

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2021

Completed
Last Updated

November 14, 2022

Status Verified

November 1, 2022

Enrollment Period

1.5 years

First QC Date

June 2, 2020

Last Update Submit

November 7, 2022

Conditions

COVID19

Outcome Measures

Primary Outcomes (1)

  • blood sampling for biobank

    development of a biobank

    2 years

Interventions

blood sampling for biobankOTHER

blood sampling for biobank

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

SARS-CoV-2 infektion (according to WHO guideline)

You may qualify if:

  • m/f age \> 18 years
  • SARS-CoV-2 infektion (according to WHO guideline)
  • hospitalisation, general ward
  • acceptable language knowledge
  • voluntary IFC and biobank appendix

You may not qualify if:

  • contra indication for blood sampling

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital Zurich, Clinical Trials Center

Zurich, 8091, Switzerland

Location

Biospecimen

Retention: SAMPLES WITH DNA

PBMCs

MeSH Terms

Conditions

COVID-19

Interventions

Blood Specimen CollectionBiological Specimen Banks

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative TechniquesHealth FacilitiesHealth Care Facilities Workforce and Services

Study Officials

  • Regina Grossmann, Dr med

    Head of Clinical Trials Center University Hospital Zurich

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Dr. med.

Study Record Dates

First Submitted

June 2, 2020

First Posted

June 4, 2020

Study Start

April 9, 2020

Primary Completion

September 30, 2021

Study Completion

September 30, 2021

Last Updated

November 14, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations

CH(1)